2025 年 ASCO 大会即将召开,百济神州有 23 篇摘要入选。本届大会上,百济神州将首次披露其两款在研实体瘤管线的临床数据,分别为BG-68501(CDK2 抑制剂)、BG-C9074(B7-H4 ADC)。目前这两个研究的数据已在 ASCO 大会官网公布,本文中就让我们来一睹为快。BG-68501:CDK2 抑制剂摘要编号:430BG-68501 是一款在研的高选择性 CDK2 抑制剂,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.